Exosomal Circular RNA as a Biomarker Platform for the Early Diagnosis of Immune-Mediated Demyelinating Disease

被引:37
|
作者
He, Jinting [1 ]
Ren, Ming [2 ,3 ]
Li, Haiqi [1 ]
Yang, Le [4 ]
Wang, Xiaofeng [5 ]
Yang, Qiwei [2 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Neurol, Changchun, Jilin, Peoples R China
[2] Jilin Univ, Hosp 2, Med Res Ctr, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Jilin, Peoples R China
[3] Jilin Univ, Hosp 2, Dept Orthoped, Changchun, Jilin, Peoples R China
[4] Peoples Hosp Jilin Prov, Dept Endocrinol, Changchun, Jilin, Peoples R China
[5] Jilin Univ, China Japan Union Hosp, Dept Stomatol, Changchun, Jilin, Peoples R China
关键词
exosome; circular RNA; immune-mediated demyelinating disease; cerebrospinal fluid; biomarker; EXPRESSION;
D O I
10.3389/fgene.2019.00860
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Exosomes can pass through the blood-brain barrier and are present in the cerebrospinal fluid (CSF). The components in exosomes, such as DNA, RNA, protein, and lipids, change greatly and are closely related to disease progression. Circular RNA (circRNA) is stable in structure and has a long half-life in exosomes without degradation. Therefore, circRNA is considered an ideal biomarker and can be used to monitor a variety of central nervous system diseases. This study aimed to investigate the expression profiles of exosomal circRNA (exo-circRNA) in CSF from patients with immune-mediated demyelinating diseases to identify suitable biomarkers for the early diagnosis of immune-mediated demyelinating diseases. circRNA expression levels in exosomes obtained from five CSF samples from immune-mediated demyelinating disease patients and five paired CSF control samples were analyzed using a hybridization array. Hierarchical clustering analysis showed that 5,095 exo-circRNAs were differentially expressed between patients with immune-mediated demyelinating diseases and paired control samples. Of these exo-circRNAs, 26 were identified as significantly differentially expressed in CSF exosomes from patients with immune-mediated demyelinating diseases (FC >= 1.5 and p <= 0.05). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis indicated that the upregulation or activation of protein tyrosine phosphatase receptor type F (PTPRF) and RAD23 homolog B, nucleotide excision repair protein (RAD23B) may be associated with the occurrence and development of immune-mediated demyelinating diseases. Then, a competing endogenous RNA network was constructed and centered on the most upregulated/downregulated exo-circRNAs to predict their function in immune-mediated demyelinating diseases. In addition, reverse transcription quantitative polymerase chain reaction results stating that hsa_circ_0087862 and hsa_circ_0012077 were validated in an independent cohort of subjects. Canonical correlation analysis results indicated a potential connection between exosomal hsa_circ_0012077 expression level and immunoglobulin G levels in CSF. Finally, the receiver operating characteristic (ROC) curve showed that when hsa_circ_0087862 or hsa_circ_0012077 was employed alone for diagnosing immune-mediated demyelinating diseases, the diagnostic accuracy was 100%. In conclusion, based on this study, exosomal hsa_circ_0087862 and hsa_circ_0012077 in CSF could be used as suitable biomarkers for the diagnosis of immune-mediated demyelinating disease based on their expression levels. Moreover, the upregulation or activation of PTPRF and RAD23B was potentially associated with the occurrence and development of immune-mediated demyelinating diseases.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] PATHOPHYSIOLOGY OF IMMUNE-MEDIATED DEMYELINATING NEUROPATHIES-PART II: NEUROLOGY
    Franssen, Hessel
    Straver, Dirk C. G.
    MUSCLE & NERVE, 2014, 49 (01) : 4 - 20
  • [32] Clinical presentation of and maintenance treatment for chronic immune-mediated demyelinating neuropathy
    Kazuki, W.
    Uchiyama, T.
    Myojin, H.
    Suzuki, S.
    Wakatsuki, R.
    Yamamoto, D.
    Sato, K.
    Ohashi, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 645 - 646
  • [33] PATHOPHYSIOLOGY OF IMMUNE-MEDIATED DEMYELINATING NEUROPATHIES-PART I: NEUROSCIENCE
    Franssen, Hessel
    Straver, Dirk C. G.
    MUSCLE & NERVE, 2013, 48 (06) : 851 - 864
  • [34] ALZHEIMER'S DISEASE BIOMARKER PROFILE IN CEREBROSPINAL FLUID OF INDIVIDUALS WITH IMMUNE-MEDIATED ENCEPHALITIS
    Fernandez Suarez, Marcos
    Surace, Ezequiel I.
    Riudavets, Miguel
    Nogues, Martin
    Vazquez, Silvia
    Sevlever, Gustavo
    Allegri, Ricardo F.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 (09) : E29 - E31
  • [35] Senile osteoporosis: Is it an immune-mediated disease?
    De Martinis, M.
    Di Benedetto, M. C.
    Mengoli, L. P.
    Ginaldi, L.
    INFLAMMATION RESEARCH, 2006, 55 (10) : 399 - 404
  • [36] Immune-mediated rippling muscle disease
    Schulte-Mattler, WJ
    Kley, RA
    Rothenfusser-Korber, E
    Böhm, S
    Brüning, T
    Hackemann, J
    Steinbrecher, A
    Düring, MV
    Voss, B
    Vorgerd, M
    NEUROLOGY, 2005, 64 (02) : 364 - 367
  • [37] Immune-mediated corneal melting disease
    Collum, LMT
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 : 78 - 80
  • [38] Holistic approaches for immune-mediated disease
    Dodds, WJ
    GREEN MOUNTAIN ESCAPE, PROCEEDINGS, 1997, : 96 - 100
  • [39] IMMUNE-MEDIATED RIPPLING MUSCLE DISEASE
    Liewluck, T.
    Goodman, B.
    Milone, M.
    MUSCLE & NERVE, 2011, 44 (04) : 627 - 627
  • [40] Transcription factors in immune-mediated disease
    Peltz, G
    CURRENT OPINION IN BIOTECHNOLOGY, 1997, 8 (04) : 467 - 473